Pipeline - Trovagene

Providing New Treatment Options Across a
Wide Array of Cancers

Demonstrated synergy of onvansertib in combination with already
approved chemotherapies and targeted therapeutics

Pipeline within a Molecule

We are developing onvansertib as part of a combination regimen across a variety of cancers and integrating a predictive clinical biomarker strategy to identify patients who are most likely to respond to treatment. The opportunity to bring new treatment options to patients in indications where there is a high medical need we believe presents significant market opportunities.

Preclinical
Phase 1
Phase 2
Acute Myeloid Leukemia – Orphan Drug Designation in the U.S. and Europe
Phase 1b/2 trial in combination with low-dose cytarabine (LDAC) or decitabine
Leukemias & Lymphomas
Metastatic Castration-Resistant Prostate
Phase 2 trial in combination with Zytiga® (abiraterone acetate)/prednisone
Colorectal (CRC)
Lung
Ovarian
Others (adrenocortical, sarcomas, head and neck, skin, liver, pancreatic, ampullary)
Solid Tumor Cancers
Triple Negative Breast
A Phase 1 trial has been completed in advanced or metastatic solid tumor cancers, including colorectal, lung, and ovarian, and published in Investigational New Drugs in 2017

Recent News

Apr 5, 2019

Trovagene Announces Update to Phase 1b/2 AML Trial Data Presented at AACR – Additional Patients Achieve Complete Response at Two Highest Dose Levels of Onvansertib

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of …

Apr 2, 2019

Early Data from Phase 2 Trial Indicates Activity of Onvansertib in Prostate Cancer Patients Showing Initial Resistance to Anti-Androgen Therapy

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of …

Apr 1, 2019

Phase 1b/2 Dose Escalation Trial of Onvansertib in Relapsed/Refractory AML Demonstrates Safety, Tolerability and Relative Durability with Complete Responses at Highest Dose Levels

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, taking a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of …